Retesting, Resampling, and Rejection: How Gummy Manufacturers Should Handle Out-of-Spec Raw Material Results

Why Out-of-Spec Raw Material Decisions Break Down in Gummy Facilities

Every gummy supplement manufacturer has written raw material specifications. Far fewer have documented, consistently followed protocols for what to do when an incoming test result falls outside those specifications. That gap — between having a spec and knowing how to act when a result fails it — is where GMP compliance collapses, batch failures begin, and FDA investigators find observations worth citing.

The problem is not usually a lack of effort. Most QA managers in gummy facilities take incoming testing seriously. The problem is procedural ambiguity. When a bloom strength result for incoming gelatin comes back low, or when a heavy metal screen on a botanical active flags above the internal limit, what exactly happens? Who decides whether to retest? How many resamples are permissible before the lot must be formally rejected? Who has authority to disposition the material, and what does that decision look like on paper? Without written answers to these questions, decisions get made informally — and informal decisions leave no audit trail.

Under 21 CFR Part 111, your quality system is required to include written procedures for sampling and testing of components, and for rejecting components that fail to meet established specifications. That requirement is not satisfied by having a spec sheet in a binder and a general understanding that "QA handles it." It is satisfied only when the full decision pathway — from initial failure through retesting, resampling, disposition, and documentation — is captured in a procedure that trained personnel can follow consistently, every time.

The Regulatory Foundation: What 21 CFR Part 111 Requires for Component Rejection

Section 111.70 of 21 CFR Part 111 establishes that you must have specifications for each component, and section 111.75 requires that you conduct at least one appropriate test or examination to verify that each component meets those specifications before use. Section 111.80 goes further, requiring that you reject any component that does not meet your specifications. What the regulation does not do — by design — is tell you exactly how to structure your retesting and resampling logic. That is left to you, and it must be written into your procedures.

This structure matters because it gives your facility flexibility, but it also means that whatever process you document becomes your standard. If your SOP says you may perform one retest on a composite resample before making a final disposition decision, then that is the process FDA will expect to see followed. Deviating from your own written procedure — even in a direction that seems more conservative — creates a documentation gap. Inspectors look for evidence that your actual practice matches your written system, and inconsistency in out-of-spec handling is a recurring observation at supplement facilities, including gummy manufacturers.

For gummy-specific ingredients, the stakes of getting this right are especially high. Gelatin, pectin, glucose syrup, active botanical extracts, and coating materials all carry ingredient-specific failure modes. A gelatin lot with low bloom strength will produce gummies that never achieve proper texture — but if that lot is conditionally released while a retest is pending and production proceeds, you have created a traceability and batch integrity problem that is very difficult to unwind. The same logic applies to a pectin lot with inconsistent gel strength or a vitamin premix with a potency result outside your acceptance range.

Retesting vs. Resampling: Understanding the Difference and When Each Applies

One of the most common procedural errors in gummy facility quality systems is conflating retesting and resampling. They are not the same, they serve different investigative purposes, and your SOP should address them separately.

Retesting means running the same test again on the same sample already pulled from the lot. A retest is appropriate when there is documented reason to suspect that the initial result was affected by a laboratory error — an instrument calibration issue, a sample preparation mistake, a reagent problem, or a procedural deviation from the test method. Retesting is not appropriate simply because you do not like the result. If you allow unlimited retests without a documented scientific rationale for each, you have converted your testing program into a result-shopping exercise. FDA investigators understand this distinction, and so does NSF during GMP certification audits.

Resampling means drawing a new sample from the original lot and testing it. Resampling is appropriate when there is a documented reason to believe the original sample may not have been representative — for example, if sampling was not performed according to your established sampling plan, or if there is evidence of sample contamination or degradation before testing. Like retesting, resampling requires a documented scientific justification. It is not a mechanism to generate additional data until you achieve a passing result.

Your SOP should specify:

• The conditions under which a retest is permissible and who must authorize it
• The conditions under which resampling is permissible and the documentation required to initiate it
• The maximum number of retests and resamples allowed before a formal rejection decision is required
• The requirement that all original test results — including failures — be retained in the batch or lot record
• The requirement that the scientific rationale for any retest or resample be documented before the additional testing occurs, not after

That last point is critical. Retroactive justification — writing a rationale for a retest after you already know the second result was passing — is a documentation integrity problem. It is the kind of pattern that, if identified during an FDA inspection, can elevate a routine quality system observation into a significantly more serious finding.

Disposition Decisions: Quarantine, Conditional Hold, and Formal Rejection

Once a raw material produces an out-of-spec result, it must be immediately placed in a clearly labeled quarantine status that physically or logistically prevents its use in production. In a gummy facility, this means the material cannot enter the weigh room, cannot be transferred to the cooking or depositing area, and cannot be included in any batch record until its disposition is formally resolved. Your quarantine system needs to be physical — a locked cage, a segregated storage zone with posted signage, or a locked pallet wrap with a visible hold tag — not just a notation in a software system that a warehouse associate might not see or understand.

During the investigation period — while you are evaluating whether a retest or resample is warranted, or while you are waiting for additional test results — the material should remain on quarantine hold. Your SOP should define the maximum allowable hold period before a disposition decision must be made. Indefinite holds on out-of-spec materials are a red flag during audits because they suggest the quality system is not actually driving decisions.

Formal rejection means the lot is documented as rejected, physically segregated and labeled with a rejection status indicator, and disposed of in accordance with your written destruction or return procedure. Rejected materials must not be re-introduced into inventory without a formal re-qualification process, which itself requires documented justification and approval. For gummy ingredients like gelatin and pectin, which are purchased in large quantities and may represent significant cost, the pressure to find a path to release rather than reject is real — but it cannot be allowed to override your written specifications and procedures. A rejected gelatin lot that gets conditionally used in production because of cost pressure, without proper documentation, is the kind of decision that produces both a batch quality failure and a serious GMP observation.

When a lot is rejected, your records should capture:

• The lot or batch number and supplier identification
• The specification that was not met and the actual test result
• The date and signature of the person making the disposition decision
• Any retesting or resampling that occurred, with results and justification
• The disposition action taken — return to supplier, destruction, or other approved action
• Confirmation that the material was physically removed from the approved storage area

Connecting Out-of-Spec Results to CAPA and Supplier Accountability

An out-of-spec raw material result is not just a disposition problem — it is a signal. How your quality system responds to that signal beyond the immediate lot disposition determines whether the same failure recurs. For gummy manufacturers, where ingredient quality has direct, measurable effects on finished product texture, potency, water activity, and shelf stability, repeated out-of-spec results from the same supplier should trigger a formal response at the supplier qualification level.

Your quality system should include a defined threshold for escalating supplier-level raw material failures into your CAPA program. A single isolated failure may warrant a supplier notification and increased incoming testing frequency. Repeated failures from the same supplier — or a pattern of borderline results that pass individually but trend toward failure — should trigger a formal CAPA investigation that addresses root cause at the vendor level. This might result in an on-site supplier audit, a request for the supplier's own deviation investigation and corrective action, or a supplier requalification process.

If you sell through Amazon or supply to retailers who require NSF GMP certification, your ability to demonstrate that out-of-spec events are investigated and resolved systematically — not just managed lot by lot — is part of what auditors and account managers evaluate. Amazon supplement compliance reviewers increasingly request documentation of your quality system response to failures, not just evidence of passing test results. A well-documented CAPA trail that shows how a gelatin supplier's recurring low bloom strength results were identified, investigated, escalated, and resolved is a significantly stronger compliance artifact than a collection of passing COAs with no context.

Building this connection — from incoming test failure through quarantine, disposition, retest or resample logic, formal rejection when warranted, and CAPA escalation when patterns emerge — is what transforms a raw material testing program from a paperwork exercise into an operational control system. For gummy supplement manufacturers working under 21 CFR Part 111, that is exactly what the regulation requires, and exactly what FDA investigators and third-party auditors are looking for when they walk into your facility.